OUR TECHNOLOGIES
The biggest problem in biomedicine today is how to account for specificity and complexity when addressing mechanisms of disease. Diseases are neither just local nor just systemic. Our drug discovery process involves using compounds/ligands we identified through experimental studies to identify new compound classes and molecular targets for drugs. In addition to developing drugs to treat diseases, Iaterion is exploiting new technological advances to uncover novel approaches to drug discovery and development.
We have over 20 years of experience of addressing Women’s Health issues which allows us to focus on how gender specific mechanisms lead to diseases in women.
Nuclear Receptors
The diverse action of NRs have made them a major target for drugs. Approximately 10–20% of current FDA‐approved drugs target nuclear receptors. Our NR modulators target multiple indications from diverse diseases where NR are culprits of pathology.
Oncology
Cancer is the second leading cause of death. Despite major advances in cancer therapy, cancer remains a devastating diagnosis to millions of people every year. At Iaterion we harness multiple different pathways related to cellular mechanisms that cancer cells employ to thrive, while ensuring in advance that our drugs deployment will not damage normal cells to reduce side-effects.